Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Yu Tashiro"'
Autor:
Yu Tashiro, Satoshi Ishitoya, Ryo Yamamoto, Kyohei Sugiyama, Hideaki Takada, Keiyu Matsumoto, Kazunari Tsuchihashi
Publikováno v:
IJU Case Reports, Vol 7, Iss 1, Pp 8-10 (2024)
Introduction Antiphospholipid syndrome is an autoimmune disease that presents with thrombus hyperplasia. Although very rare, this disease is reported to become severe after the surgical invasion and other interventions. To our knowledge, there are no
Externí odkaz:
https://doaj.org/article/8bad5a4aca8c49039a2b7f14dd36c3b6
Autor:
Katsuhiro Ito, Takashi Kobayashi, Takahiro Kojima, Kensuke Hikami, Takeshi Yamada, Kosuke Ogawa, Kenji Nakamura, Naoto Sassa, Akira Yokomizo, Takashige Abe, Kazunari Tsuchihashi, Shuichi Tatarano, Junichi Inokuchi, Ryotaro Tomida, Maki Fujiwara, Atsushi Takahashi, Kazumasa Matsumoto, Kosuke Shimizu, Hiromasa Araki, Ryoma Kurahashi, Yu Osaki, Yu Tashiro, Masayuki Uegaki, Osamu Ogawa, Hiroshi Kitamura, Hiroyuki Nishiyama
Publikováno v:
Cancer Medicine, Vol 10, Iss 10, Pp 3188-3196 (2021)
Abstract Background The benefits of pembrolizumab in patients with advanced urothelial carcinoma (UC) and impaired performance status (PS) remain unknown. This study assessed the safety and efficacy of pembrolizumab in patients with platinum‐refrac
Externí odkaz:
https://doaj.org/article/98ad661f861345338f17b09eccbd721b
Autor:
Minoru, Kato, Takashi, Kobayashi, Yoshiyuki, Matsui, Katsuhiro, Ito, Kensuke, Hikami, Takeshi, Yamada, Kosuke, Ogawa, Kenji, Nakamura, Naoto, Sassa, Akira, Yokomizo, Takashige, Abe, Kazunari, Tsuchihashi, Shuichi, Tatarano, Junichi, Inokuchi, Ryotaro, Tomida, Maki, Fujiwara, Atsushi, Takahashi, Kazumasa, Matsumoto, Kosuke, Shimizu, Hiromasa, Araki, Ryoma, Kurahashi, Yu, Ozaki, Yu, Tashiro, Masayuki, Uegaki, Takahiro, Kojima, Junji, Uchida, Osamu, Ogawa, Hiroyuki, Nishiyama, Hiroshi, Kitamura, Tomohiro, Fukui
Publikováno v:
International Journal of Urology. 28:1261-1267
Objectives To investigate the impact of the number of cycles and objective response to chemotherapy on overall survival in patients with metastatic urothelial carcinoma treated with pembrolizumab. Methods This multicenter, retrospective study include
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::230091139cfec3f877229fc5cc1e3c86
https://doi.org/10.1111/iju.14686
https://doi.org/10.1111/iju.14686
Autor:
Takeshi Yamada, Kosuke Shimizu, Yu Osaki, Maki Fujiwara, Hiroshi Kitamura, Osamu Ogawa, Atsushi Takahashi, Kazumasa Matsumoto, Hiromasa Araki, Katsuhiro Ito, Ryotaro Tomida, Takahiro Kojima, Ryoma Kurahashi, Kensuke Hikami, Hiroyuki Nishiyama, Takashige Abe, Yu Tashiro, Takashi Kobayashi, Shuichi Tatarano, Akira Yokomizo, Naoto Sassa, Kosuke Ogawa, Kenji Nakamura, Masayuki Uegaki, Kazunari Tsuchihashi, Junichi Inokuchi
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 10, Iss 10, Pp 3188-3196 (2021)
Cancer Medicine, Vol 10, Iss 10, Pp 3188-3196 (2021)
Background The benefits of pembrolizumab in patients with advanced urothelial carcinoma (UC) and impaired performance status (PS) remain unknown. This study assessed the safety and efficacy of pembrolizumab in patients with platinum‐refractory UC a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::489e1c791dc1728bcb0297373035701d
https://doi.org/10.1002/cam4.3863
https://doi.org/10.1002/cam4.3863
Autor:
Shusuke Akamatsu, Osamu Ogawa, Takashi Kobayashi, Hideto Ota, Takashi Mizowaki, Kenji Takayama, Kiyonao Nakamura, Toshinari Yamasaki, Takahiro Inoue, Rihito Aizawa, Yu Tashiro, Takashi Ogata
Publikováno v:
International Journal of Urology. 28:749-755
Objective To assess the efficacy of combination of prostate-targeted treatment and metastasis-directed therapy for oligometastatic prostate cancer. Methods We retrospectively evaluated the clinical outcomes of synchronously diagnosed oligometastatic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::087a904d1376b7d2694feadff976ee4e
https://doi.org/10.1111/iju.14567
https://doi.org/10.1111/iju.14567
Publikováno v:
Neurourology and Urodynamics. 39:2527-2534
Aim To assess real-world treatment profiles, including the time to and reasons for discontinuation or drug switching, treatment reinitiation, and postdiscontinuation follow-up in patients receiving antimuscarinics or s3-agonists for overactive bladde
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::faf3a9673469c66dc6bed754cd38f58d
https://doi.org/10.1002/nau.24527
https://doi.org/10.1002/nau.24527